RU2016129079A - Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы - Google Patents
Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы Download PDFInfo
- Publication number
- RU2016129079A RU2016129079A RU2016129079A RU2016129079A RU2016129079A RU 2016129079 A RU2016129079 A RU 2016129079A RU 2016129079 A RU2016129079 A RU 2016129079A RU 2016129079 A RU2016129079 A RU 2016129079A RU 2016129079 A RU2016129079 A RU 2016129079A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- components
- eicosapentaenoic acid
- amount
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- 229940012843 omega-3 fatty acid Drugs 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 title 1
- 239000006014 omega-3 oil Substances 0.000 title 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 5
- 210000001328 optic nerve Anatomy 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Claims (11)
1. Композиция или набор компонентов, содержащие по меньшей мере 5 г эйкозапентаеновой кислоты и докозагексаеновой кислоты, при массовом соотношении ЭПК : ДГК от 1:1 до 5:1, для применения в лечении, облегчении или предотвращении поражения зрительного нерва.
2. Композиция или набор компонентов по п. 1, отличающаяся тем, что поражение зрительного нерва выбрано из группы, состоящей из поражения зрительного нерва, вызванного глаукомой, ишемической невропатии зрительного нерва (ION) и неврита глазного нерва, или любой их комбинации.
3. Композиция или набор компонентов по п. 1 для применения в лечении, облегчении или предотвращении неврита глазного нерва.
4. Композиция или набор компонентов по п. 1 для применения в лечении, облегчении или предотвращении глаукомы.
5. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что применяемое количество эйкозапентаеновой кислоты и докозагексаеновой кислоты составляет от 5 г до 15 г в день.
6. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что применяемое количество эйкозапентаеновой кислоты и докозагексаеновой кислоты больше 7,5 г в день.
7. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что применяемое количество эйкозапентаеновой кислоты и докозагексаеновой кислоты составляет от 7,5 г до 10 г в день.
8. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что применяемое количество эйкозапентаеновой кислоты больше 3,0 г в день.
9. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что композиция представляет собой фармацевтическую композицию или набор компонентов представляет собой фармацевтический набор компонентов.
10. Композиция или набор компонентов для применения по п. 1, отличающаяся тем, что композиция представляет собой пищевую композицию, или набор компонентов представляет собой пищевой набор компонентов.
11. Композиция или набор компонентов по п. 1, отличающаяся тем, что количество эйкозапентаеновой кислоты и докозагексаеновой кислоты выбрано таким, чтобы массовое отношение арахидоновая кислота/эйкозапентаеновая кислота в крови лежало в диапазоне от 0,8 до 3, предпочтительно от 1 до 1,5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/077356 WO2015090394A1 (en) | 2013-12-19 | 2013-12-19 | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016129079A true RU2016129079A (ru) | 2018-01-24 |
| RU2667640C1 RU2667640C1 (ru) | 2018-09-21 |
Family
ID=50137601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016129079A RU2667640C1 (ru) | 2013-12-19 | 2013-12-19 | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160331712A1 (ru) |
| EP (1) | EP3082795B1 (ru) |
| JP (1) | JP6389893B2 (ru) |
| KR (1) | KR101898358B1 (ru) |
| CN (1) | CN105828813A (ru) |
| AU (1) | AU2013407946B2 (ru) |
| BR (1) | BR112016014182A2 (ru) |
| CA (1) | CA2934600C (ru) |
| CY (1) | CY1123942T1 (ru) |
| DK (1) | DK3082795T3 (ru) |
| ES (1) | ES2813383T3 (ru) |
| HR (1) | HRP20201221T1 (ru) |
| HU (1) | HUE050205T2 (ru) |
| IL (1) | IL246254B (ru) |
| LT (1) | LT3082795T (ru) |
| MX (1) | MX2016007803A (ru) |
| MY (1) | MY185412A (ru) |
| PH (1) | PH12016501159A1 (ru) |
| PL (1) | PL3082795T3 (ru) |
| PT (1) | PT3082795T (ru) |
| RS (1) | RS60862B1 (ru) |
| RU (1) | RU2667640C1 (ru) |
| UA (1) | UA117274C2 (ru) |
| WO (1) | WO2015090394A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
| CN114786480B (zh) * | 2019-10-30 | 2024-03-29 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| AU2021217358A1 (en) | 2020-02-06 | 2022-09-08 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| EP4329753A1 (en) | 2021-04-30 | 2024-03-06 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
| JP5240757B2 (ja) * | 2005-02-22 | 2013-07-17 | 持田製薬株式会社 | 神経再生促進剤 |
| US20070265340A1 (en) * | 2006-01-05 | 2007-11-15 | Shalwitz Robert A | Treatment of fatty liver |
| EP1900378A1 (en) | 2006-08-31 | 2008-03-19 | Novartis AG | Pharmaceutical compositions for the treatment of fungal infections |
| JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防／改善または治療剤 |
| BRPI0924012A2 (pt) * | 2009-04-17 | 2019-09-24 | Cela Vista Pharmaceuticals Ltd | processo para obtenção de uma composição rica em ácidos graxos ômega 3 de um óleo de origem marinha, com um teor de af interior 90 mg/g composição, suplemento nutricional produto alimentar, composição farmacêutica, e, uso de um composto |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
| RU2597793C2 (ru) * | 2011-01-25 | 2016-09-20 | Нестек С.А. | Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных |
| BR112013020802A2 (pt) * | 2011-02-18 | 2016-10-04 | Nestec Sa | métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| BR112014005546A2 (pt) * | 2011-09-12 | 2017-03-21 | Georgiou Tassos | ácidos graxos ômega para tratamento de doenças |
-
2013
- 2013-12-19 AU AU2013407946A patent/AU2013407946B2/en active Active
- 2013-12-19 BR BR112016014182A patent/BR112016014182A2/pt not_active Application Discontinuation
- 2013-12-19 UA UAA201607999A patent/UA117274C2/uk unknown
- 2013-12-19 RS RS20200971A patent/RS60862B1/sr unknown
- 2013-12-19 PT PT138301841T patent/PT3082795T/pt unknown
- 2013-12-19 MY MYPI2016702245A patent/MY185412A/en unknown
- 2013-12-19 DK DK13830184.1T patent/DK3082795T3/da active
- 2013-12-19 KR KR1020167019609A patent/KR101898358B1/ko active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077356 patent/WO2015090394A1/en active Application Filing
- 2013-12-19 PL PL13830184T patent/PL3082795T3/pl unknown
- 2013-12-19 MX MX2016007803A patent/MX2016007803A/es unknown
- 2013-12-19 CN CN201380081739.3A patent/CN105828813A/zh active Pending
- 2013-12-19 HU HUE13830184A patent/HUE050205T2/hu unknown
- 2013-12-19 US US15/106,475 patent/US20160331712A1/en not_active Abandoned
- 2013-12-19 LT LTEP13830184.1T patent/LT3082795T/lt unknown
- 2013-12-19 CA CA2934600A patent/CA2934600C/en active Active
- 2013-12-19 RU RU2016129079A patent/RU2667640C1/ru active
- 2013-12-19 EP EP13830184.1A patent/EP3082795B1/en active Active
- 2013-12-19 ES ES13830184T patent/ES2813383T3/es active Active
- 2013-12-19 JP JP2016540609A patent/JP6389893B2/ja active Active
-
2016
- 2016-06-15 PH PH12016501159A patent/PH12016501159A1/en unknown
- 2016-06-15 IL IL246254A patent/IL246254B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,354 patent/US10905671B2/en active Active
-
2020
- 2020-08-04 HR HRP20201221TT patent/HRP20201221T1/hr unknown
- 2020-08-13 CY CY20201100758T patent/CY1123942T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013407946A2 (en) | 2016-08-25 |
| IL246254A0 (en) | 2016-07-31 |
| UA117274C2 (uk) | 2018-07-10 |
| IL246254B (en) | 2021-04-29 |
| EP3082795B1 (en) | 2020-05-20 |
| JP2017501169A (ja) | 2017-01-12 |
| WO2015090394A1 (en) | 2015-06-25 |
| PT3082795T (pt) | 2020-08-27 |
| ES2813383T3 (es) | 2021-03-23 |
| CY1123942T1 (el) | 2022-03-24 |
| HUE050205T2 (hu) | 2020-11-30 |
| PL3082795T3 (pl) | 2020-11-16 |
| CN105828813A (zh) | 2016-08-03 |
| LT3082795T (lt) | 2020-11-10 |
| BR112016014182A2 (pt) | 2017-08-08 |
| PH12016501159A1 (en) | 2016-08-15 |
| AU2013407946B2 (en) | 2017-09-07 |
| RU2667640C1 (ru) | 2018-09-21 |
| US20160331712A1 (en) | 2016-11-17 |
| EP3082795A1 (en) | 2016-10-26 |
| HRP20201221T1 (hr) | 2020-11-13 |
| MX2016007803A (es) | 2017-08-10 |
| CA2934600C (en) | 2018-11-20 |
| DK3082795T3 (da) | 2020-08-24 |
| KR101898358B1 (ko) | 2018-09-12 |
| JP6389893B2 (ja) | 2018-09-12 |
| US10905671B2 (en) | 2021-02-02 |
| KR20160093729A (ko) | 2016-08-08 |
| CA2934600A1 (en) | 2015-06-25 |
| AU2013407946A1 (en) | 2016-08-04 |
| RS60862B1 (sr) | 2020-11-30 |
| US20190192466A1 (en) | 2019-06-27 |
| MY185412A (en) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502307A1 (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| WO2014074552A3 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| JP2016512245A5 (ja) | マイボーム腺を標的とする組成物 | |
| RU2016129079A (ru) | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы | |
| NZ729290A (en) | Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism | |
| JP2015527386A5 (ru) | ||
| AR095182A1 (es) | Composiciones de estatinas y ácidos grasos omega-3 | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2015143248A5 (ru) | ||
| HRP20191963T1 (hr) | Smjesa masnih kiselina za primjenu u liječenju upalnih patologija | |
| WO2016027216A3 (en) | A synergistic edible oil composition | |
| HRP20171431T1 (hr) | Terapijska parenteralna primjena krilovog ulja | |
| RU2017142720A (ru) | Сложные эфиры для лечения офтальмологических воспалительных заболеваний | |
| UA112446C2 (uk) | Застосування омега-жирних кислот для лікування захворювання | |
| WO2014039964A3 (en) | Compounds and methods for modulating vascular injury | |
| WO2016040570A3 (en) | Dietary emulsion formulations and methods for using the same | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| BR112017007428A2 (pt) | composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença | |
| MY181997A (en) | Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid | |
| WO2017077528A3 (en) | Methods and pharmaceutical compositions for treatment of lung inflammation | |
| MX2015007085A (es) | Composiciones de acido omega-3 pentanoico y metodos de uso. | |
| JP2016501248A5 (ru) | ||
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| EA201692398A1 (ru) | Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. |